Chemistry:SC-5233

From HandWiki
SC-5233
SC-5233.svg
Clinical data
Other names6,7-Dihydrocanrenone; 7-Desthioacetylspironolactone; 20-Spirox-4-ene-3,20-dione
Routes of
administration
By mouth
Drug classAntimineralocorticoid; Progestogen; Steroidal antiandrogen
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H30O3
Molar mass342.479 g·mol−1
3D model (JSmol)

SC-5233, also known as 6,7-dihydrocanrenone or 20-spirox-4-ene-3,20-dione, is a synthetic, steroidal antimineralocorticoid of the spirolactone group which was developed by G. D. Searle & Company in the 1950s but was never marketed.[1][2] It was the first synthetic antagonist of the mineralocorticoid receptor to have been identified and tested in humans.[1][3] The drug was found to lack appreciable oral bioavailability and to be of low potency when administered parenterally,[4] but it nonetheless produced a mild diuretic effect in patients with congestive heart failure.[1] SC-8109, the 19-nor (19-demethyl) analogue, was developed and found to have improved oral bioavailability and potency, but still had low potency.[5] Spironolactone (SC-9420; Aldactone) followed and had both good oral bioavailability and potency, and was the first synthetic antimineralocorticoid to be marketed.[3] It has about 46-fold higher oral potency than SC-5233.[6]

SC-5233 is the propionic acid lactone of testosterone (androst-4-en-17β-ol-3-one) and is also known 3-(3-oxo-17β-hydroxyandrost-4-en-17α-yl)propionic acid γ-lactone or as 17α-(2-carboxyethyl)testosterone γ-lactone.[7] It is the unsubstituted parent or prototype compound of the spirolactone family of steroidal antimineralocorticoids.[2][8]

Similarly to other spirolactones like canrenone and spironolactone, SC-5233 has some antiandrogenic activity and antagonizes the effects of testosterone in animals.[7] In addition, along with SC-8109, it has been found to possess potent progestogenic activity.[9]

References

  1. 1.0 1.1 1.2 E. Buchborn; K. D. Bock (14 December 2013). Diuresis and Diuretics / Diurese und Diuretica: An International Symposium Herrenchiemsee, June 17th–20th, 1959 Sponsored by CIBA / Ein Internationales Symposium Herrenchiemsee, 17.–20. Juni 1959 Veranstaltet mit Unterstützung der CIBA. Springer-Verlag. pp. 224,261. ISBN 978-3-642-49716-2. https://books.google.com/books?id=BJKhBgAAQBAJ&pg=PA261. 
  2. 2.0 2.1 Gyorgy Szasz; Zsuzsanna Budvari-Barany (19 December 1990). Pharmaceutical Chemistry of Antihypertensive Agents. CRC Press. pp. 82–. ISBN 978-0-8493-4724-5. https://books.google.com/books?id=LMl4Sd38q4kC&pg=PA82%7Cdate%3D19+December+1990%7Cpublisher%3DCRC+Press%7Cisbn%3D978-0-8493-4724-5%7Cpages%3D82%E2%80%9383%7D%7D%3C%2Fref%3E. 
  3. 3.0 3.1 Dennis V. Cokkinos (6 November 2014). Introduction to Translational Cardiovascular Research. Springer. pp. 61–. ISBN 978-3-319-08798-6. https://books.google.com/books?id=DP05BQAAQBAJ&pg=PA61. 
  4. The British Encyclopaedia of Medical Practice: Medical progress. Butterworth & Company. 1961. p. 302. https://books.google.com/books?id=wvIfAQAAMAAJ. "Cena and Kagawa first synthesized 3-(3-oxo-17β-hydroxy-4-androsten-17α-yl)-propionic acid-gamma-lactone and later prepared its 19-nor analogue. These compounds were designated SC-5233 and SC-8109, respectively. Both have anti-aldosterone activity and most of the early work on aldosterone antagonism was done with their aid. SC-5233 is not appreciably absorbed when given by mouth and the parenteral dose is large. As in the case of certain other steroids the 19-nor derivative was an improvement on the parent compound (Klyne, 1959). SC-8109 is well absorbed from the alimentary tract, but the dose is about 2 g daily." 
  5. Milan L. Brandon (1 January 1962). Corticosteroids in medical practice. Thomas. ISBN 9780398002152. https://books.google.com/books?id=UtVqAAAAMAAJ. 
  6. "30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development". J. Endocrinol. 234 (1): T125–T140. July 2017. doi:10.1530/JOE-16-0600. PMID 28634268. 
  7. 7.0 7.1 "Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone". J. Pharmacol. Exp. Ther. 126 (2): 123–30. 1959. PMID 13665517. "[SC-5233] (total dose of 5 mg/rat) partially blocked the effects of testosterone propionate on the seminal vesicles and prostate in similar animals.". 
  8. Janos Fischer; C. Robin Ganellin (24 August 2010). Analogue-based Drug Discovery II. John Wiley & Sons. pp. 361–. ISBN 978-3-527-63212-1. https://books.google.com/books?id=h2Kd8ci4Ln8C&pg=PA361. 
  9. "Progestational activity of certain steroid-17-spirolactones". Proc. Soc. Exp. Biol. Med. 99 (2): 451–2. 1958. doi:10.3181/00379727-99-24380. PMID 13601900.